AFP Specific Liver Tumor Vaccines Inhibit Hepatocellular Carcinoma Growth
DOI: 10.12677/HJS.2012.13003, PDF, HTML, XML, 下载: 3,482  浏览: 9,667 
作者: 刘扬*:同济大学附属第十人民医院肝胆外科;王跃如:上海交通大学附属第一人民医院内科;Lisa H Butterfield:美国匹兹堡大学肿瘤研究所
关键词: 甲胎蛋白树突状细胞细胞因子AFP特异性T细胞Alpha-Fetoprotein (AFP); Dendritic Cell; Cytokine; AFP-Specific T Cells
摘要: 目的:甲胎蛋白作为一种肿瘤特异性抗原,是临床上诊断肝癌的重要指标。本研究中,我们检测了AFP特异性T细胞的体外抗肿瘤免疫活性。方法:我们采用经过AFP抗原决定簇肽刺激或慢病毒转染的树突状细胞(dendritic cells, DC),活化AFP特异性的CD4+T细胞和CD8+T细胞(肝癌疫苗),并在体外检测了这群T细胞对人肝癌细胞HepG2的杀伤活性。结果:本研究结果显示,AFP特异性的CD4+T细胞和CD8+T细胞体外能有效杀伤HepG2细胞,上调培养体系中IL-2IFN-γTNF-α、穿孔素、颗粒酶的水平,对于T细胞活化的负调控因子IL-10,具有显著的抑制作用。结论:DC活化后的AFP特异性T细胞具有显著的体外抗肿瘤免疫活性,为肝细胞癌的临床免疫治疗提供了依据。
Abstract: Objective: Alpha-fetoprotein (AFP), a tumor-associated antigen for hepatocellular carcinoma (HCC), is an established biomarker for hepatocellular cancer (HCC). In this study, we detected antitumor activity of AFP specific T cells in vitro. Methods: We created a lentivirus expressing AFP (Lenti-AFP) and investigated the antitumor activity of AFP-specific CD4+ and CD8+ T cells(liver tumor vaccines), which were activated by either AFP peptide-pulsed or Lenti-AFP-engineered DC in vitro. Results: Our research demonstrated that the AFP-specific T cells could efficiently kill HepG2 cells, by significantly increasing the level of IL-2, IFN-γTNF-αperforin and granzyme B, as well as by inhibiting the production of IL-10 (a negative regulator of T cell activation). Conclusion: AFP-specific CD4+ and CD8+ T cells (liver tumor vaccines) which were activated by either AFP peptide-pulsed or Lenti-AFP-engineered DC have obviously antitumor activity. This study provides new insight into the design of DC activated antigen-specific T cell-based clinical trials
文章引用:刘扬, 王跃如, Lisa HButterfield. AFP特异性肝癌疫苗抑制肝细胞癌生长[J]. 外科, 2012, 1(3): 11-17.


[1] L. H. Butterfield, A. Ribas, D. M. Potter and J. S. Economou. Spontaneous and vaccine induced AFP-specific T cell phenol- types in Subjects with AFP-positive hepatocellular cancer. Can- cer Immunol. Immunother, 2007, 56: 1931-1943.
[2] L. H. Butterfield, A. Ribas, V. B. Dissette, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four AFP peptides. Clinical Cancer Research, 2006, 12: 2817-2825.
[3] Y. Liu, S. Daley, V. N. Evdokimova, et al. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP- positive hepatocellular cancer. Journal of Immunology, 2006, 177: 712-721.
[4] Y. Liu, L. H. Butterfield, X.-H. Fu, et al. Lentivirally engineered DC activate AFP-specific CD8+/CD4+ T cells whcich inhibit hepatocellular carcinoma growth in vitro and in vivo. Interna- tional Journal of Oncology, 2011, 39: 245-253.
[5] V. N. Evdokimova, Y. Liu, D. M. Potter and L. H. Butterfield. AFP specific CD4+ helper T cell responses in healthy donors and HCC patients. Journal of Immunotherapy, 2007, 30: 425-437.
[6] 刘扬, 陆崇德, 吴孟超等. HLA-A*0201限制性AFP抗原决定簇肽特异性肝癌疫苗的制备[J]. 同济大学学报(医学版), 2009, 30: 30-33.
[7] A. K. Palucka, H. Ueno, J. Fay, et al. Dendritic cells: A critical player in cancer therapy? Journal of Immunology, 2008, 31: 793-805.